Skip to main content
TransThera Sciences (Nanjing), Inc. logo

TransThera Sciences (Nanjing), Inc. — Investor Relations & Filings

Ticker · 2617 ISIN · CNE100006T02 HKEX Manufacturing
Open in API
Filings indexed 70 across all filing types
Latest filing 2026-05-19 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2617

About TransThera Sciences (Nanjing), Inc.

https://www.transthera.com

TransThera Sciences (Nanjing), Inc. is a clinical-stage, R&D-driven biopharmaceutical company focused on the discovery, development, and commercialization of innovative small molecule therapies. Established in 2014, the company employs a clinical demand-oriented approach to address diseases with significant unmet medical needs. TransThera's pipeline is dedicated to generating first-in-class, best-in-class, and highly differentiated treatments, primarily targeting therapeutic areas such as oncology, inflammatory diseases, and cardiovascular conditions.

Recent filings

Filing Released Lang Actions
PLACING OF NEW H SHARES UNDER GENERAL MANDATE
Regulatory Filings
2026-05-19 English
VOLUNTARY ANNOUNCEMENT TransThera Sciences (Nanjing) Publishes Clinical Results of Tinengotinib as Monotherapy and in Combination with Atezolizumab for Advanced Solid Tumors on Nature Communications
Regulatory Filings Classification · 65% confidence The document is a voluntary announcement under Hong Kong Listing Rules informing shareholders and investors of the publication of clinical results in an external academic journal (Nature Communications). It does not contain financial data, management changes, dividends, or other specific categories. It is not a formal investor presentation or regulatory financial report but rather a general corporate announcement. Therefore, it falls into the fallback category of general regulatory announcements (RNS).
2026-05-17 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026 (Re-submission)
Regulatory Filings
2026-05-06 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
Regulatory Filings
2026-05-06 English
ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2025
Environmental & Social Information Classification · 90% confidence The document is a full-fledged Environmental, Social and Governance (ESG) Report for 2025 by TransThera Sciences (Nanjing), Inc., containing detailed disclosures on ESG governance structure, compliance, materiality analysis, stakeholder communication, green development, talent empowerment, and more. It is not merely an announcement but the substantive report itself. This clearly matches the Environmental & Social Information category.
2026-04-23 English
ANNUAL REPORT 2025
Annual Report Classification · 100% confidence The document is explicitly titled '2025 ANNUAL REPORT' and contains standard sections such as 'Chairman's Statement', 'Management Discussion and Analysis', 'Corporate Information', and detailed financial statements (Consolidated Statement of Profit or Loss, Financial Position, etc.). It covers the company's full-year performance, business review, and audited financial data, which aligns perfectly with the definition of a 10-K (Annual Report). FY 2025
2026-04-23 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.